Descriptive only
Level 2 or 3 hypoglycemia (participants)
Type 1 diabetes
longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
3
Randomized trials
4
Treatments
114
Participants
4
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 3 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline HbA1c (percent) effect modifier, prognostic factor; 3 of 3 |
|---|---|
| NCT02617654 S002261 | 7.35 |
| ADJUST-T1D S002321 | 7.75 |
| S003007 S003007 | 7.25 |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagOutcome assessment, definition: confounded with design: not stated 1, Participants with severe hypoglycemia, undefined 1, severe hypoglycemia, undefined 1
- NoteOutcome assessment, time point: selected time points span 12 to 65 weeks
- NoteOutcome assessment, analysis set: mixed: randomized 2, safety 1
- NoteRisk of bias, funding: mixed: mixed 2, non_industry 1
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02617654 | 65 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2015 | age 18 or older; T1D 5 years or longer; HbA1c 45 to 75 mmol/mol; fasting C-peptide above 1.5 pmol/L |
| ADJUST-T1D | 26 | randomized | Participants with severe hypoglycemia, undefined | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2023 | age 18 to 65; type 1 diabetes on AID; BMI 30 or more |
| S003007 | 12 | safety | severe hypoglycemia, undefined | not stated | not stated | not stated | not stated | not stated | double_blind | non_industry | 2024 | age 18 to 60; type 1 diabetes 2 years or more; BMI 30 or more |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT02617654 | A1 | PLACEBO | 65 | arm, events | 0 / 8 | R0012710:Results | |||
| NCT02617654 | A2 | LIRA_SC_1p8MG_QD | 65 | arm, events | 0 / 10 | R0012710:Results | |||
| ADJUST-T1D | A1 | SEMA_SC_1p0MG_QW | 26 | arm, events | 2 / 36 | registry:outcomes | |||
| ADJUST-T1D | A2 | PLACEBO | 26 | arm, events | 2 / 36 | registry:outcomes | |||
| S003007 | A1 | TIRZ_SC_5MG_QW | 12 | arm, events | 0 / 12 | R0014500:Results | |||
| S003007 | A2 | PLACEBO | 12 | arm, events | 0 / 12 | R0014500:Results |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.